Traws Pharma updates influenza prophylaxis program guidance
- Traws Pharma announced it is preparing an updated toxicology data package to clear regulatory paths for an upcoming influenza trial.
- Following the program guidance update, market data showed the company's shares trading down at $0.82.
- The company intends to submit the information in the third quarter of 2026 to enable its Phase 2a challenge study.
Clinical-stage biopharmaceutical firm Traws Pharma (NASDAQ:TRAW) updated guidance for its influenza prophylaxis program to enable a planned Phase 2a trial.
This update follows regulatory feedback from the United Kingdom health authority regarding requirements for its therapeutic candidate.
The company expects to resubmit the updated data package during the third quarter of 2026.
Regulatory officials are anticipated to provide a formal response within 30 days of receiving the resubmitted package.
Following the announcement, Traws Pharma's share price was down at $0.82.
The therapeutic candidate has demonstrated broad laboratory activity against multiple seasonal influenza strains.
The organization also plans to profile alternative molecules to expand its broader respiratory treatment portfolio.
